Logo
x

Search category

Subscribe Now

STADA

STADA and Xbrane Report P-III Study Results of Ximluci (biosimilar, ranibizumab) for the Treatment of Neovascular Age-Related Macular Degeneration

STADA and Xbrane Report P-III Study Results of Ximluci (biosimilar, ranibizumab) for the Treatment of Neovascular Age-Related Macu...

  • June 23, 2023
STADA and Xbrane Launch Ximluci (biosimilar, ranibizumab) for Ophthalmic Conditions in the EU

STADA and Xbrane Launch Ximluci (biosimilar, ranibizumab) for Ophthalmic Conditions in the EU

  • April 3, 2023
STADA and Xbrane Receives the MHRA’s Approval for Ximluci (biosimilar, ranibizumab) to Treat Retinal Diseases

STADA and Xbrane Receives the MHRA’s Approval for Ximluci (biosimilar, ranibizumab) to Treat Retinal Diseases

  • January 6, 2023
STADA and Xbrane Receive EC’s Marketing Authorization of Ximluci (biosimilar, ranibizumab) for Retinal Disorders

STADA and Xbrane Receive EC’s Marketing Authorization of Ximluci (biosimilar, ranibizumab) for Retinal Disorders

  • November 11, 2022
STADA and Xbrane Receive EMA’s CHMP Positive Opinion for Ximluci (biosimilar, ranibizumab)

STADA and Xbrane Receive EMA’s CHMP Positive Opinion for Ximluci (biosimilar, ranibizumab)

  • September 16, 2022
STADA and Alvotech Launch AVT02 (biosimilar, adalimumab) for the Treatment of Inflammatory Conditions

STADA and Alvotech Launch AVT02 (biosimilar, adalimumab) for the Treatment of Inflammatory Conditions

  • June 9, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.